NASDAQ · Key Statistics

Journey Medical Corporation (DERM) P/E Ratio, ROE & Key Statistics

$3.90 NASDAQ: DERM Market Cap $110.08M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Journey Medical Corporation (DERM), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.-23.29
P/B ratioShare price divided by book value per share.3.77
P/S ratioMarket value divided by annual revenue.1.76
PEG ratioP/E divided by the earnings growth rate.-0.73
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.45.87
EV / RevenueEnterprise value against annual revenue.1.81
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.-4.29%
Free cash flow yieldFree cash flow as a percentage of market value.-6.99%
Price / free cash flowMarket value divided by free cash flow.-14.30

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.43.20%
Operating marginRevenue left after operating costs.-2.89%
Net marginRevenue left after every cost, including tax and interest.-7.34%
Return on equityProfit as a percentage of shareholders’ equity.-16.07%
Return on assetsProfit as a percentage of total assets.-4.91%
Return on capital employedOperating profit against the capital the business uses.-3.99%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.1.48
Quick ratioThe same, excluding inventory.1.34
Cash ratioCash alone against current liabilities.0.65
Debt to equityTotal borrowings against shareholders’ equity.0.79
Debt to assetsTotal borrowings against total assets.0.26
Interest coverageHow many times operating profit covers the interest bill.-0.55

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.−$0.47
Book value per shareShareholders’ equity divided by shares outstanding.$1.15
Market capitalisationShare price times shares outstanding.$110.08M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$126.21M
EmployeesReported headcount.41

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Journey Medical Corporation (DERM) statistics — frequently asked questions

What is Journey Medical Corporation's P/E ratio?

Journey Medical Corporation (DERM) trades on a price-to-earnings ratio of -23.29. A negative P/E means the company reported a loss, so the ratio is not a meaningful valuation measure.

What is Journey Medical Corporation's return on equity?

Journey Medical Corporation (DERM) reports a return on equity of -16.07%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Journey Medical Corporation carry?

Journey Medical Corporation (DERM) has a debt-to-equity ratio of 0.79, which compares total borrowings with shareholders' equity.

What is Journey Medical Corporation's profit margin?

Journey Medical Corporation (DERM) keeps -7.34% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Drug Manufacturers - Specialty & Generic stocks

TEVA P/E 94.73ZTS P/E 13.82VTRS ROE -4.24%ELAN ROE -2.24%RDY P/E 39.94ALKS key statisticsAMRX P/E 50.49LNTH P/E 24.54SUPN ROE -4.14%BHC key statisticsAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.